| Number of patients (n = 40) |
---|---|
Mean patient age (range) | 56 (29–79) |
Surgical procedure | |
 Segmentectomy | 12 |
 Mastectomy | 28 |
Tumor histology | |
 Ductal carcinoma | 39 |
 Lobular carcinoma | 1 |
Tumor histological grade | |
 1 | 3 |
 2 | 17 |
 3 | 20 |
Tumor biomarker status | |
 ER/PR positive | 32 |
 HER2 positive | 7 |
 Triple-negative | 7 |
Disease stage | |
 1A/1B | 18 |
 2A/2B | 16 |
 3A/3B/3C | 6 |
Treatment intent with systemic therapy | |
 Adjuvant therapy following surgical resection | 28 |
 Neoadjuvant prior to surgical resection | 8 |
 None | 4 |
Systemic therapy | |
 Chemotherapy only | 9 |
  TCa | 5 |
  FEC-Db | 3 |
  TACc | 1 |
 Chemotherapy followed by endocrine therapy | 19 |
  TC followed by TAMd | 12 |
  FEC-D followed by TAM or AIe | 7 |
 Endocrine therapy alone | 8 |
  TAM | 7 |
  AI | 1 |